Ireland vs South Korea: The number of people with susceptibility test result for rifampicin
Ireland
80
in 2021
South Korea
82.06
in 2021
Ireland rank
94th
South Korea rank
91st
The number of people with susceptibility test result for rifampicin over time
- Ireland
- South Korea
How they compare
South Korea currently reports 82.06 against 80 in Ireland, a difference of 2.06.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Ireland ahead.
Ireland ranks 94th and South Korea ranks 91st of 146 countries.
Ireland has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ireland | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 90.79 | 84.51 | 6.28 | Ireland |
| 2020s | 85.83 | 85.46 | 0.3689 | Ireland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Ireland or South Korea?
- South Korea, at 82.06 against 80 in Ireland as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Ireland and South Korea?
- 2.06, with South Korea ahead.
- How many years of comparable data are there for Ireland and South Korea?
- 5 years are reported by both, from 2017 to 2021.
- How do Ireland and South Korea rank globally for the number of people with susceptibility test result for rifampicin?
- Ireland ranks 94th and South Korea ranks 91st of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.